Affymax Inc AFFY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.04
- Bid/Ask
- $0.02 / $0.04
- Market Cap
- $26,243.07
- Volume/Avg
- 125 / 25,625
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- http://www.affymax.com
Competitors
Valuation
|
Metric
|
AFFY
|
RHHBY
|
AMGN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 11.21 | 14.64 |
Price/Book Value | — | 5.58 | 23.45 |
Price/Sales | — | 2.92 | 5.21 |
Price/Cash Flow | — | 10.75 | 16.40 |
Price/Earnings
AFFY
RHHBY
AMGN
Financial Strength
|
Metric
|
AFFY
|
RHHBY
|
AMGN
|
|---|---|---|---|
Quick Ratio | 15.88 | 0.99 | 1.03 |
Current Ratio | 20.81 | 1.35 | 1.65 |
Interest Coverage | — | 14.93 | 3.73 |
Quick Ratio
AFFY
RHHBY
AMGN
Profitability
|
Metric
|
AFFY
|
RHHBY
|
AMGN
|
|---|---|---|---|
Return on Assets (Normalized) | −24.40% | 17.03% | 11.62% |
Return on Equity (Normalized) | −1,578.31% | 53.42% | 169.05% |
Return on Invested Capital (Normalized) | −1,578.31% | 26.30% | 19.71% |
Return on Assets
AFFY
RHHBY
AMGN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xgrnlwcjd | Zkxr | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gksncqdj | Dmcjz | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Djkwsczz | Cnkrn | $99.5 Bil | |
MRNA
| Moderna Inc | Tjrqbznk | Ncly | $38.8 Bil | |
ARGX
| argenx SE ADR | Ntxwdgqw | Shzyg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Cvkhnzmz | Vtgy | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pbnfsvds | Lpgyhz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wchwqzwqd | Lwztd | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Slxblnvfg | Dvbpc | $12.5 Bil | |
INCY
| Incyte Corp | Vdttdxcy | Vyyzbl | $11.6 Bil |